Surgery Partners (SGRY) Aktievy
Surgery Partners, Inc. äger och driver tillsammans med sina dotterbolag ett nätverk av kirurgiska kliniker och tillhörande tjänster i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 5/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 4/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
Inga risker upptäckta för SGRY från våra riskkontroller.
SGRY Community Fair Values
Create NarrativeSee what 7 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Surgery Partners, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$15.82 |
| 52 veckors högsta | US$24.10 |
| 52 veckors lägsta | US$11.41 |
| Beta | 1.95 |
| 1 månads förändring | 18.41% |
| 3 månaders förändring | 32.72% |
| 1 års förändring | -28.83% |
| 3 års förändring | -63.76% |
| 5 års förändring | -75.78% |
| Förändring sedan börsintroduktionen | -14.16% |
Senaste nyheter och uppdateringar
Analysartikel • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...
Uppdatering av berättelse • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.
Uppdatering av berättelse • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.Recent updates
Analysartikel • Jun 19
Surgery Partners (SGRY) Stock Could Be 19% Undervalued As Growth And Debt Concerns Build
Recent commentary on Surgery Partners (SGRY) has focused on slowing sales volume growth, softer revenue growth expectations, and ongoing high debt levels. This combination appears to be affecting sentiment toward the stock. See our latest analysis for Surgery Partners. At a share price of $14.55, Surgery Partners has seen a 30 day share price return of 7.86% and a 90 day share price return of 23.31%. However, the 1 year total shareholder return is down 24.61%, pointing to some recent momentum...Uppdatering av berättelse • Jun 15
SGRY: Reset Expectations And Steady Guidance Will Shape Future Multiple Potential
Analysts cut the fair value estimate for Surgery Partners stock by $4 to $14, reflecting updated assumptions around revenue growth, profit margins, the discount rate, and a lower future P/E multiple, despite recent mixed price target moves at Jefferies. Analyst Commentary Recent research shows mixed views on Surgery Partners, with some analysts adjusting price targets in both directions over a short period.Uppdatering av berättelse • Jun 01
SGRY: Margin Repair And Payer Mix Reset Will Support 2026 EBITDA Recovery
The analyst-derived fair value estimate for Surgery Partners has shifted from about $18.80 to roughly $17.95, as analysts factor in recent price target cuts tied to Q4 margin pressures, a softer 2026 EBITDA outlook, and concerns around payer mix, anesthesia costs, and a slower M&A contribution. Analyst Commentary Recent Street research around Surgery Partners has been active, with multiple firms revisiting their models after Q4 results and updated 2026 guidance.
Uppdatering av berättelse • May 02
SGRY: Margin Pressures Will Ease As 2026 M&A Upside Reemerges
Narrative Update on Surgery Partners Analysts have trimmed the average price target for Surgery Partners by a few dollars into the mid to high teens, citing Q4 EBITDA and margin shortfalls, a weaker payer mix, anesthesia related cost pressures, softer 2026 guidance, and reduced expectations for M&A contribution. Analyst Commentary Price targets across the Street have been revised lower into a tighter band, generally in the mid to low US$20s and mid to high teens, following the Q4 miss and 2026 EBITDA guidance that came in below prior expectations.Uppdatering av berättelse • Apr 18
SGRY: Margin Pressures Will Ease As M&A Optionality Reshapes 2026 Outlook
Analysts have reduced the average price target for Surgery Partners by roughly $8 to $10 per share to a range of about $14 to $24, citing Q4 EBITDA shortfalls, margin pressures from payer and insurance mix shifts, anesthesia related costs, and softer 2026 guidance that excludes potential M&A. Analyst Commentary Recent research shows that while price targets have moved lower across the Street, several bullish analysts still see upside potential for Surgery Partners relative to current trading levels.Uppdatering av berättelse • Apr 04
SGRY: Margin Repair And Payer Mix Management Will Support A Constructive 2026 Reset
The analyst price target for Surgery Partners has been reduced from about $25.45 to about $18.80. Analysts cite weaker Q4 EBITDA, margin pressure from a tougher payer and insurance mix, anesthesia-related cost pressures, and more cautious 2026 guidance as key drivers of their updated views.Uppdatering av berättelse • Mar 21
SGRY: Margin Reset And M&A Optionality Will Counter Anesthesia And Payer Mix Pressures
Narrative Update on Surgery Partners The analyst price target for Surgery Partners has moved lower by several dollars into a $14 to $24 range, as analysts factor in recent Q4 EBITDA shortfalls, weaker margins, anesthesia and payer mix headwinds, and management's 2026 guidance that sits below prior consensus and assumes limited M&A. Analyst Commentary Recent Street commentary on Surgery Partners centers on Q4 earnings that came in below expectations, margin pressure tied to anesthesia costs, and a less favorable payer mix.Uppdatering av berättelse • Mar 06
SGRY: Margin Reset And M&A Optionality Are Expected To Ease Payer Mix Pressures
The analyst fair value estimate for Surgery Partners has been reduced from $33.00 to $25.00 as analysts factor in lower Q4 EBITDA, margin pressure related to payer mix and anesthesia costs, and softer 2026 guidance that assumes fewer deals than previously modeled. Analyst Commentary Street research has broadly reset expectations on Surgery Partners, with several firms lowering their price targets after Q4 results and the updated 2026 outlook.Uppdatering av berättelse • Feb 20
SGRY: New Baylor Partnership Will Set Up Future Multiple Rebound Potential
Analysts have kept their $18.00 price target for Surgery Partners unchanged, citing consistent assumptions regarding revenue growth, profit margins, and future P/E as support for this view. What's in the News Surgery Partners agreed to a new partnership with Baylor Scott & White Health to jointly own The Physicians Centre Hospital, a 16 bed facility in Bryan, Texas, alongside physicians (Key Developments).Uppdatering av berättelse • Feb 06
SGRY: Payer Mix Pressures Will Set Up Future Multiple Rebound Potential
Analysts have reduced their price target on Surgery Partners to US$18 from US$24, citing weaker earnings visibility from payer mix and volume pressures, a higher discount rate, more conservative revenue growth assumptions, and an adjustment to a lower future P/E multiple. Analyst Commentary Recent research updates on Surgery Partners point to a reset in expectations, with several firms cutting price targets across the board.Uppdatering av berättelse • Jan 23
SGRY: Asset Divestitures And Deleveraging Are Expected To Reset Payer Mix Pressures
Narrative Update Analysts have reduced their price targets on Surgery Partners to a range of roughly US$18 to US$31, citing lower earnings visibility tied to payer mix and volume pressures, slower M&A activity, and updated guidance that still assumes a favorable backdrop for asset divestitures and ambulatory surgery center demand. Analyst Commentary Across recent research updates, analysts have generally reduced price targets for Surgery Partners into the US$18 to US$31 range while still highlighting several areas that they see as supportive for the equity story.Uppdatering av berättelse • Jan 09
SGRY: Upcoming Divestitures And Deleveraging Will Support A Constructive 2025 Reset
Analysts have trimmed their price targets on Surgery Partners, resulting in a modest change in estimated fair value from about $25.73 to $25.45, as they factor in payer mix pressure, softer recent performance, slower M&A activity, and updated expectations for volumes and earnings visibility. Analyst Commentary Recent research paints a mixed picture for Surgery Partners, with price targets moving lower but opinions split on how temporary the current pressures might be.Uppdatering av berättelse • Dec 25
SGRY: Upcoming Asset Divestitures Are Expected To Drive Material Balance Sheet Deleveraging
Analysts have trimmed their fair value estimate for Surgery Partners to $33 from $36. This reflects lower price targets across the Street as they factor in softer volume trends, payer mix headwinds, reduced earnings visibility and a slower M&A cadence, partially offset by confidence in long term ASC tailwinds and de-leveraging from asset divestitures.Uppdatering av berättelse • Dec 11
SGRY: Upcoming Divestitures And Deleveraging Will Drive A Constructive Reset In 2025
Surgery Partners price target has been revised lower, with analysts trimming expectations by mid single digit dollars per share to reflect weaker than expected recent performance, payer mix and volume pressures, slower M&A activity, and reduced near term earnings visibility, even as they highlight supportive long term fundamentals and a still constructive outlook on asset divestitures and deleveraging. Analyst Commentary Analysts are broadly revising models to reflect weaker near term trends, yet most still frame the stock as a valuation reset rather than a change in the long term thesis.Uppdatering av berättelse • Nov 27
SGRY: Upcoming Divestitures And Deleveraging Will Drive Recovery In 2025
Analysts have lowered their price target for Surgery Partners from approximately $27.91 to $25.73. They cite recent earnings misses, payer mix headwinds, and delayed acquisitions as primary factors for the revision.Uppdatering av berättelse • Nov 12
SGRY: Asset Divestitures And Acquisition Pipeline Will Drive Recovery Ahead
The analyst price target for Surgery Partners has decreased from $31 to approximately $27.91. Analysts cite lowered guidance due to slowing volume and payer mix trends, a delay in acquisitions, and a more cautious outlook for near-term growth.Seeking Alpha • Sep 08
Surgery Partners: Deleveraging Needs To Be The Priority
Summary Surgery Partners now trades at fair value after multiple compression, with returns on capital still lagging and leverage elevated, justifying my Hold rating. Q2 results were decent, but cash flow conversion and ambitious H2 margin targets highlight execution risks and limited room for error. Business economics show SGRY is capital intensive, with ROIC below the cost of capital, so growth currently destroys value unless returns improve. To upgrade my stance, I need to see sustained high-teen margins, clear deleveraging, and a shift to higher organic growth over acquisitions. Read the full article on Seeking AlphaNy berättelse • May 26
Ambulatory Surgery Trends And Aging Will Expand Market Reach
Growth is driven by rising surgical case volumes in lower-cost centers and expanded specialties, supported by demographic trends and strategic network expansion.Seeking Alpha • Jan 30
Surgery Partners: A Buyout Could Be Justifiable Around This Level
Summary Surgery Partners received a non-binding offer from Bain Capital to acquire the rest of the company for $25.75 per share, valuing it at $3.25 billion. In the past, the stock had been pricey, but this is no longer the case based on current pricing. In recent years, financial performance has been solid and improving, particularly when it comes to cash flows. The market is cautiously optimistic about the offer, suggesting potential for a higher bid, but significant upside is unlikely. Read the full article on Seeking AlphaAnalysartikel • Dec 08
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues Pushing Shares 28% Lower
The Surgery Partners, Inc. ( NASDAQ:SGRY ) share price has fared very poorly over the last month, falling by a...Analysartikel • Nov 11
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysartikel • Oct 24
Market Cool On Surgery Partners, Inc.'s (NASDAQ:SGRY) Revenues
It's not a stretch to say that Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.4x right...Analysartikel • Oct 05
Surgery Partners (NASDAQ:SGRY) Has Some Way To Go To Become A Multi-Bagger
If you're looking for a multi-bagger, there's a few things to keep an eye out for. Typically, we'll want to notice a...Analysartikel • Jul 25
Surgery Partners, Inc. (NASDAQ:SGRY) Soars 25% But It's A Story Of Risk Vs Reward
Surgery Partners, Inc. ( NASDAQ:SGRY ) shareholders would be excited to see that the share price has had a great month...Analysartikel • Jul 13
Here's Why Surgery Partners (NASDAQ:SGRY) Has A Meaningful Debt Burden
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Analysartikel • Jun 21
Slowing Rates Of Return At Surgery Partners (NASDAQ:SGRY) Leave Little Room For Excitement
To find a multi-bagger stock, what are the underlying trends we should look for in a business? One common approach is...Analysartikel • May 31
We Think Shareholders Are Less Likely To Approve A Pay Rise For Surgery Partners, Inc.'s (NASDAQ:SGRY) CEO For Now
Key Insights Surgery Partners will host its Annual General Meeting on 6th of June CEO J. Evans' total compensation...Analysartikel • Apr 24
Surgery Partners, Inc.'s (NASDAQ:SGRY) Share Price Matching Investor Opinion
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.2x is...Analysartikel • Mar 18
Surgery Partners' (NASDAQ:SGRY) Returns Have Hit A Wall
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysartikel • Feb 27
Surgery Partners (NASDAQ:SGRY) Takes On Some Risk With Its Use Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Dec 19
The Price Is Right For Surgery Partners, Inc. (NASDAQ:SGRY)
There wouldn't be many who think Surgery Partners, Inc.'s ( NASDAQ:SGRY ) price-to-sales (or "P/S") ratio of 1.5x is...Analysartikel • Oct 26
Returns Are Gaining Momentum At Surgery Partners (NASDAQ:SGRY)
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Analysartikel • Sep 17
Does Surgery Partners (NASDAQ:SGRY) Have A Healthy Balance Sheet?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 26
Are Investors Undervaluing Surgery Partners, Inc. (NASDAQ:SGRY) By 35%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Surgery Partners fair value estimate is US$52.34 Surgery...Aktieägarnas avkastning
| SGRY | US Healthcare | US Marknad | |
|---|---|---|---|
| 7D | 8.7% | 5.9% | -2.5% |
| 1Y | -28.8% | 22.1% | 19.0% |
Avkastning vs industri: SGRY presterade sämre än US Healthcare branschen som gav 22.1 % under det senaste året.
Avkastning vs Marknaden: SGRY presterade sämre än US marknaden som gav 19 % under det senaste året.
Prisvolatilitet
| SGRY volatility | |
|---|---|
| SGRY Average Weekly Movement | 4.7% |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: SGRY har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SGRY s veckovolatilitet ( 5% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2004 | 16,000 | J. Evans | www.surgerypartners.com |
Surgery Partners, Inc. äger och driver tillsammans med sina dotterbolag ett nätverk av kirurgiska kliniker och tillhörande tjänster i USA. Företaget tillhandahåller ambulerande kirurgiska centra och kirurgiska sjukhus som erbjuder icke akuta kirurgiska ingrepp inom olika specialiteter, inklusive ortopedi och smärtlindring, oftalmologi, gastroenterologi och allmänkirurgi. Företaget erbjuder akutmottagningar, tilläggstjänster såsom läkarmottagningar och diagnostiska tester, läkarmottagningar med flera specialiteter, akutvårdsanläggningar samt anestesitjänster.
Surgery Partners, Inc. Sammanfattning av grunderna
| SGRY grundläggande statistik | |
|---|---|
| Börsvärde | US$2.05b |
| Vinst(TTM) | -US$76.10m |
| Intäkter(TTM) | US$3.34b |
0.6x
P/S-förhållande-26.9x
P/E-förhållandeÄr SGRY övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SGRY resultaträkning (TTM) | |
|---|---|
| Intäkter | US$3.34b |
| Kostnad för intäkter | US$2.58b |
| Bruttovinst | US$763.30m |
| Övriga kostnader | US$839.40m |
| Intäkter | -US$76.10m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.59 |
| Bruttomarginal | 22.83% |
| Nettovinstmarginal | -2.28% |
| Skuld/egenkapitalförhållande | 80.4% |
Hur har SGRY utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/29 16:15 |
| Aktiekurs vid dagens slut | 2026/06/26 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Surgery Partners, Inc. bevakas av 21 analytiker. 11 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Steven Valiquette | Barclays |
| Sarah James | Barclays |
| Andrew Mok | Barclays |